Earth Science Tech, Inc. (ETST) Plans to Battle Op
Post# of 333
(Total Views: 225)
Posted On: 04/27/2018 8:24:11 PM
Earth Science Tech, Inc. (ETST) Plans to Battle Opioid Addiction with Human Clinical Trials in 2019
- Centers for Disease Control and Prevention, in March 2018, estimated ‘economic burden’ of opioid misuse at $78.5 billion annually
- ETST plans to complete white paper, begin human clinical trials by 2019; company intends to investigate drugs that combine mineral element and cannabinoid industrial hemp oil
- Goal for biotech company is to fight opioid addiction with over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug
Earth Science Tech, Inc. (OTC: ETST) is planning to fight opioid addiction in the near future by completing its white paper and beginning human clinical trials in 2019. The epidemic is projected to claim nearly 500,000 American lives by 2027, according to a study by STAT (http://nnw.fm/9Twid).
The ETST white paper and planned human clinical studies deal with the measure of the efficacy of combination drugs against opioid dependency. The company will investigate the synergies between mineral elements and full spectrum cannabinoid industrial hemp with the goal of developing OTC and generic drugs that treat opioid addiction.
ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets. In addition to drug research, it also performs R&D testing for medical devices. The company holds several subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; KannaBidioiD, Inc.; and Canna Inno Laboratories, Inc., based in Montreal, Canada.
The company’s proposed OTC drug would be intended to reduce the cravings of opioid addicts. The other would be a generic designed to reduce the danger of side effects and make the first drug more effective, according to ETST. The purpose of the human trial is to develop a methodology that prevents fatal overdoses and relieves the side effects of withdrawal.
The Centers for Disease Control and Prevention (CDC), in a March 2018 revised report, estimated the ‘economic burden’ of opioid misuse at $78.5 billion annually in the U.S., including in that figure health care, addiction treatment and the involvement of the justice system. The National Institute on Drug Abuse terms it a national health crisis (http://nnw.fm/se3kA).
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Centers for Disease Control and Prevention, in March 2018, estimated ‘economic burden’ of opioid misuse at $78.5 billion annually
- ETST plans to complete white paper, begin human clinical trials by 2019; company intends to investigate drugs that combine mineral element and cannabinoid industrial hemp oil
- Goal for biotech company is to fight opioid addiction with over-the-counter (OTC) treatment drug and a cannabinoid companion generic drug
Earth Science Tech, Inc. (OTC: ETST) is planning to fight opioid addiction in the near future by completing its white paper and beginning human clinical trials in 2019. The epidemic is projected to claim nearly 500,000 American lives by 2027, according to a study by STAT (http://nnw.fm/9Twid).
The ETST white paper and planned human clinical studies deal with the measure of the efficacy of combination drugs against opioid dependency. The company will investigate the synergies between mineral elements and full spectrum cannabinoid industrial hemp with the goal of developing OTC and generic drugs that treat opioid addiction.
ETST is a biotech company focused on the cannabinoid, pharmaceutical and nutraceutical markets. In addition to drug research, it also performs R&D testing for medical devices. The company holds several subsidiaries, including Earth Science Pharmaceutical, Inc.; Cannabis Therapeutics, Inc.; KannaBidioiD, Inc.; and Canna Inno Laboratories, Inc., based in Montreal, Canada.
The company’s proposed OTC drug would be intended to reduce the cravings of opioid addicts. The other would be a generic designed to reduce the danger of side effects and make the first drug more effective, according to ETST. The purpose of the human trial is to develop a methodology that prevents fatal overdoses and relieves the side effects of withdrawal.
The Centers for Disease Control and Prevention (CDC), in a March 2018 revised report, estimated the ‘economic burden’ of opioid misuse at $78.5 billion annually in the U.S., including in that figure health care, addiction treatment and the involvement of the justice system. The National Institute on Drug Abuse terms it a national health crisis (http://nnw.fm/se3kA).
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)